

# CITATION REPORT

List of articles citing

## Evaluation of Galcanezumab for the Prevention of Episodic Migraine: The EVOLVE-1 Randomized Clinical Trial

DOI: 10.1001/jamaneurol.2018.1212  
JAMA Neurology, 2018, 75, 1080-1088.

**Source:** <https://exaly.com/paper-pdf/71096678/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
353	Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018. <b>2018</b> , 58 Suppl 3, 276-290		39
352	Galcanezumab in chronic migraine: The randomized, double-blind, placebo-controlled REGAIN study. <b>2018</b> , 91, e2211-e2221		234
351	Patient satisfaction, health care resource utilization, and acute headache medication use with galcanezumab: results from a 12-month open-label study in patients with migraine. <b>2018</b> , 12, 2413-2424		16
350	Basic Considerations for the Use of Monoclonal Antibodies in Migraine. <b>2018</b> , 58, 1689-1696		16
349	Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. <b>2018</b> , 19, 121		33
348	The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. <b>2019</b> , 59, 1-18		198
347	Emerging drugs for migraine treatment: an update. <b>2018</b> , 23, 301-318		34
346	Treatment Effects with Multiple Outcomes. <b>2018</b> ,		0
345	The Role of Calcitonin Gene Related Peptide (CGRP) in Neurogenic Vasodilation and Its Cardioprotective Effects. <b>2018</b> , 9, 1249		80
344	Neue Substanzen zur Prophylaxe der Migräne. <b>2018</b> , 19, 30-34		
343	A new opportunity after migraine treatment failure?. <b>2018</b> , 392, 2241-2242		0
342	Recommendations on the Use of Anti-CGRP Monoclonal Antibodies in Children and Adolescents. <b>2018</b> , 58, 1658-1669		38
341	Galcanezumab: First Global Approval. <b>2018</b> , 78, 1769-1775		25
340	100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies. <b>2018</b> , 58, 1347-1357		23
339	Neurological treatment goes bacterial. <b>2018</b> , 17, 738-740		
338	Was kann die Antikörpertherapie in der Neurologie?. <b>2019</b> , 20, 20-29		
337	Is targeting CGRP the right pathway to prevent migraine?. <b>2019</b> , 394, 984-986		4

336	Recent and updated pharmacotherapy of migraine. <b>2019</b> , 35, 571-578	3
335	Signifikant weniger Migr�etage. <b>2019</b> , 21, 26-26	
334	Anti-CGRP monoclonal antibodies: breakthrough in migraine therapeutics. <b>2019</b> , 23, 26-33	2
333	Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk. <b>2019</b> , 59, 1421-1426	14
332	The treatment efficacy of galcanezumab for migraine: A meta-analysis of randomized controlled trials. <b>2019</b> , 186, 105428	2
331	Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review. <b>2019</b> , 59 Suppl 2, 20-32	46
330	Error in Table. <i>JAMA Neurology</i> , <b>2019</b> , 76, 872	17.2
329	Two randomized migraine studies of galcanezumab: Effects on patient functioning and disability. <b>2019</b> , 93, e508-e517	17
328	Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). <b>2019</b> , 20, 75	22
327	Effects of Anti-Calcitonin Gene-Related Peptide for Migraines: A Systematic Review with Meta-Analysis of Randomized Clinical Trials. <b>2019</b> , 20,	23
326	[Migraine - therapy in transition]. <b>2019</b> , 161, 50-58	
325	Preventive Treatment for Episodic Migraine. <b>2019</b> , 37, 753-770	16
324	Novel Medications for the Treatment of Migraine. <b>2019</b> , 59, 1597-1608	17
323	Monoclonal Antibodies to CGRP or Its Receptor for Migraine Prevention. <b>2019</b> , 15, 717-724.e1	4
322	Targeting calcitonin gene-related peptide: a new era in migraine therapy. <b>2019</b> , 394, 1765-1774	129
321	Brain structure and function related to headache. <b>2019</b> , 39, 1603-1605	1
320	A potent fluorescent calcitonin gene-related peptide analogue enables visualization of receptor internalization. <b>2019</b> , 111, e24126	5
319	Pediatric Migraine: An Update. <b>2019</b> , 37, 815-833	11

318	Non-invasive vagus nerve stimulation (nVNS) for the preventive treatment of episodic migraine: The multicentre, double-blind, randomised, sham-controlled PREMIUM trial. <b>2019</b> , 39, 1475-1487	35
317	Monoclonal antibodies for the prevention of migraine. <b>2019</b> , 19, 1307-1317	28
316	Recent Advances in Pharmacotherapy for Episodic Migraine. <b>2019</b> , 33, 1053-1071	21
315	Primary headache disorders: Five new things. <b>2019</b> , 9, 233-240	19
314	CSD-Induced Arterial Dilatation and Plasma Protein Extravasation Are Unaffected by Fremanezumab: Implications for CGRP's Role in Migraine with Aura. <b>2019</b> , 39, 6001-6011	25
313	Neue Therapien der Migräne. <b>2019</b> , 2, 207-217	1
312	How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice. <b>2019</b> , 20, 49	26
311	Efficacy of galcanezumab in patients with chronic migraine and a history of preventive treatment failure. <b>2019</b> , 39, 931-944	21
310	More precise phenotyping of cluster headache using prospective attack reports. <b>2019</b> , 26, 1303-e85	8
309	Anti-CGRP and anti-CGRP receptor monoclonal antibodies as antimigraine agents. Potential differences in safety profile postulated on a pathophysiological basis. <b>2019</b> , 116, 16-21	11
308	Therapeutic novelties in migraine: new drugs, new hope?. <b>2019</b> , 20, 37	54
307	Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. <b>2019</b> , 90, 939-944	16
306	Peripheral and central nervous system distribution of the CGRP neutralizing antibody [I] galcanezumab in male rats. <b>2019</b> , 39, 1241-1248	41
305	Once-monthly galcanezumab for the prevention of migraine in adults: an evidence-based descriptive review and potential place in therapy. <b>2019</b> , 15, 557-569	6
304	CGRP and the Trigeminal System in Migraine. <b>2019</b> , 59, 659-681	107
303	Migraine treatment: the doors for the future are open, but with caution and prudence. <b>2019</b> , 77, 115-121	4
302	CGRP and headache: a brief review. <b>2019</b> , 40, 99-105	30
301	Are antimigraine drugs that influence CGRP levels justified?. <b>2019</b> , 71, 624-635	1

300	Invited Commentary on Preventive Anti-Migraine Therapy (PAMT). <b>2019</b> , 21, 14	5
299	Psychometric Validation of the Role Function Restrictive Domain of the Migraine Specific Quality-of-Life Questionnaire Version 2.1 Electronic Patient-Reported Outcome in Patients With Episodic and Chronic Migraine. <b>2019</b> , 59, 756-774	8
298	CGRP Antagonists for the Treatment of Chronic Migraines: a Comprehensive Review. <b>2019</b> , 23, 29	22
297	TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities. <b>2019</b> , 12,	39
296	A new era for migraine: Pharmacokinetic and pharmacodynamic insights into monoclonal antibodies with a focus on galcanezumab, an anti-CGRP antibody. <b>2019</b> , 39, 1284-1297	36
295	Health state utilities associated with attributes of migraine preventive treatments based on patient and general population preferences. <b>2019</b> , 28, 2359-2372	8
294	Effect of Galcanezumab Following Treatment Cessation in Patients With Migraine: Results From 2 Randomized Phase 3 Trials. <b>2019</b> , 59, 834-847	20
293	New Trends in Migraine Pharmacology: Targeting Calcitonin Gene-Related Peptide (CGRP) With Monoclonal Antibodies. <b>2019</b> , 10, 363	35
292	Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials. <b>2019</b> , 39, 1164-1179	28
291	Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. <b>2019</b> ,	3
290	Migraine Management Standard Therapies and New Strategies. <b>2019</b> , 34, 1-7	
289	NEWS IN BRIEF. <b>2019</b> , 34, 12	
288	ICYMI. <b>2019</b> , 34, 8-10	
287	Multimodale Programme und neue Therapien gegen den Kopfschmerz. <b>2019</b> , 20, 51-59	
286	What's New in the Treatment of Migraine?. <b>2019</b> , 39, 352-359	9
285	Calcitonin gene-related peptide: the new era of migraine therapy. <b>2019</b> , 1, FDD14	0
284	How much do calcitonin gene-related peptide monoclonal antibodies improve the quality of life in migraine? A patient's perspective. <b>2019</b> , 32, 395-404	9
283	CGRP-based Migraine Therapeutics: How Might They Work, Why So Safe, and What Next?. <b>2019</b> , 2, 2-8	16

282	Analysis of Initial Nonresponders to Galcanezumab in Patients With Episodic or Chronic Migraine: Results From the EVOLVE-1, EVOLVE-2, and REGAIN Randomized, Double-Blind, Placebo-Controlled Studies. <b>2019</b> , 59, 192-204	17
281	Calcitonin Gene-Related Peptide Antagonists in the Treatment of Episodic Migraine. <b>2019</b> , 105, 1121-1129	7
280	Getting closer to a cure for migraine. <b>2019</b> , 15, 64-65	4
279	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <b>2019</b> , 20, 6	158
278	The most important advances in headache research in 2018. <b>2019</b> , 18, 5-6	4
277	Problematic presentation and use of efficacy measures in current trials of CGRP monoclonal antibodies for episodic migraine prevention: A mini-review. <b>2020</b> , 40, 122-126	4
276	Cluster Headache and other Trigeminal Autonomic Cephalgias. <b>2020</b> ,	2
275	Future Therapies for Trigeminal Autonomic Cephalalgias: Cluster Headache and Related Conditions. <b>2020</b> , 257-264	
274	Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials. <b>2020</b> , 27, 609-618	18
273	Rapid Onset of Effect of Galcanezumab for the Prevention of Episodic Migraine: Analysis of the EVOLVE Studies. <b>2020</b> , 60, 348-359	24
272	Population Pharmacokinetics of Galcanezumab, an Anti-CGRP Antibody, Following Subcutaneous Dosing to Healthy Individuals and Patients With Migraine. <b>2020</b> , 60, 229-239	11
271	Positive response to galcanezumab following treatment failure to onabotulinumtoxinA in patients with migraine: post hoc analyses of three randomized double-blind studies. <b>2020</b> , 27, 542-549	10
270	Placebo and nocebo phenomena in anti- CGRP monoclonal antibody trials for migraine prevention: a meta-analysis. <b>2020</b> , 267, 1158-1170	9
269	Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies. <b>2020</b> , 60, 110-123	20
268	Do different treatment strategies of galcanezumab have a similar effect on migraine?. <b>2020</b> , 27, e19-e20	
267	The Headache Pipeline: Excitement and Uncertainty. <b>2020</b> , 60, 190-199	7
266	Development and Internal Validation of a Multivariable Prediction Model for Individual Episodic Migraine Attacks Based on Daily Trigger Exposures. <b>2020</b> , 60, 2364-2379	6
265	An Evidence-Based Review of Galcanezumab for the Treatment of Migraine. <b>2020</b> , 9, 403-417	1

264	Efficacy and Contextual (Placebo) Effects of CGRP Antibodies for Migraine: Systematic Review and Meta-analysis. <b>2020</b> , 60, 1542-1557	10
263	Interrelations between migraine-like headache and persistent post-traumatic headache attributed to mild traumatic brain injury: a prospective diary study. <b>2020</b> , 21, 134	8
262	Reducing Episodic Cluster Headaches: Focus on Galcanezumab. <b>2020</b> , 13, 1591-1599	1
261	Utilization of B12 for the treatment of chronic migraine. <b>2020</b> , 34, 479-491	2
260	Galcanezumab for the prevention of cluster headache. <b>2020</b> , 20, 1133-1142	3
259	Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials). <b>2020</b> , 21, 123	6
258	Efficacy of Galcanezumab for Migraine Prevention in Patients With a Medical History of Anxiety and/or Depression: A Post Hoc Analysis of the Phase 3, Randomized, Double-Blind, Placebo-Controlled REGAIN, and Pooled EVOLVE-1 and EVOLVE-2 Studies. <b>2020</b> , 60, 2202-2219	5
257	Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. <b>2020</b> , 255, 143-170	16
256	Three new drugs for the prevention of migraine. <b>2020</b> , 58, 151-156	
255	Safety and efficacy of galcanezumab in Taiwanese patients: a post-hoc analysis of phase 3 studies in episodic and chronic migraine. <b>2020</b> , 36, 1653-1666	1
254	Prophylaxe der Migräne mit monoklonalen Antikörpern gegen CGRP oder den CGRP-Rezeptor. <b>2020</b> , 39, S2-S24	0
253	Kopfschmerz News der DMKG. <b>2020</b> , 39, 88-92	
252	Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). <b>2020</b> , 41, 487-488	9
251	Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. <b>2020</b> , 19, 814-825	57
250	Efficacy and safety of galcanezumab for prevention of migraine headache in Japanese patients with episodic migraine: A phase 2 randomized controlled clinical trial. <b>2020</b> , 3, 251581632093257	8
249	CGRP inhibitors for migraine prophylaxis: a safety review. <b>2020</b> , 19, 1237-1250	19
248	Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine. <b>2020</b> , 60, 1734-1742	20
247	Migraine Headache Day Response Rates and the Implications to Patient Functioning: An Evaluation of 3 Randomized Phase 3 Clinical Trials of Galcanezumab in Patients With Migraine. <b>2020</b> , 60, 2304-2319	2

246	Migraine. <b>2020</b> , 383, 1866-1876	123
245	Evaluation of injection-site-related adverse events with galcanezumab: a post hoc analysis of phase 3 studies in participants with migraine. <b>2020</b> , 20, 194	1
244	Monoclonal antibodies as a preventive therapy for migraine: A meta-analysis. <b>2020</b> , 195, 105900	8
243	Update in migraine preventive treatment. <b>2020</b> , 255, 1-27	1
242	Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study. <b>2020</b> , 21, 62	21
241	Galcanezumab: A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache. <b>2020</b> , 80, 893-904	1
240	Migraine Care in the Era of COVID-19: Clinical Pearls and Plea to Insurers. <b>2020</b> , 60, 833-842	60
239	No central action of CGRP antagonising drugs in the GTN mouse model of migraine. <b>2020</b> , 40, 924-934	22
238	Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. <b>2020</b> , 211, 107528	54
237	Intravenous Migraine Treatment in Children and Adolescents. <b>2020</b> , 24, 45	1
236	Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clinical trials. <b>2020</b> , 21, 79	7
235	Calcitonin Gene-Related Peptide Antagonists for the Prevention of Migraine: Highlights From Pivotal Studies and the Clinical Relevance of This New Drug Class. <b>2020</b> , 54, 795-803	2
234	Galcanezumab: a monoclonal antibody for migraine prophylaxis. <b>2020</b> , 31, 33-34	1
233	A comprehensive overview and safety evaluation of fremanezumab as a preventive therapy for migraine. <b>2020</b> , 19, 537-543	
232	Phase 3 randomized, placebo-controlled study of galcanezumab in patients with chronic cluster headache: Results from 3-month double-blind treatment. <b>2020</b> , 40, 935-948	47
231	Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine - an updated systematic review and meta-analysis. <b>2020</b> , 20, 57	46
230	Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1). <b>2020</b> , 40, 241-254	111
229	Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials. <b>2020</b> , 21, 14	7



228	Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan. <b>2020</b> , 60, 576-588	10
227	Menstrual migraine: what it is and does it matter?. <b>2021</b> , 268, 2355-2363	10
226	Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. <b>2020</b> , 20, 25	18
225	Efficacy and safety of galcanezumab for preventive treatment of migraine: a systematic review and meta-analysis. <b>2021</b> , 268, 2364-2376	7
224	Assessment of immunogenicity from galcanezumab phase 3 trials in patients with episodic or chronic migraine. <b>2020</b> , 40, 978-989	6
223	CGRP pathway monoclonal antibodies for cluster headache. <b>2020</b> , 20, 947-953	7
222	Efficacy and Safety of Galcanezumab for the Preventive Treatment of Migraine: A Narrative Review. <b>2020</b> , 37, 2034-2049	5
221	Prophylaxe episodischer und chronischer Migräne mit CGRP(Rezeptor)-Antikörpern. <b>2020</b> , 22, 28-39	
220	Cost of fremanezumab, erenumab, galcanezumab and onabotulinumtoxinA associated adverse events, for migraine prophylaxis in Spain. <b>2021</b> , 21, 285-297	2
219	Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. <b>2021</b> , 41, 340-352	19
218	Calcitonin Gene-Related Peptide Monoclonal Antibody Use for the Preventive Treatment of Refractory Headache Disorders in Adolescents. <b>2021</b> , 114, 62-67	14
217	Update on Calcitonin Gene-Related Peptide Antagonism in the Treatment of Migraine. <b>2021</b> , 39, 1-19	7
216	Eptinezumab for the preventive treatment of migraine. <b>2021</b> , 11, 113-121	2
215	Treatment of migraine: a review of disease burden and an update on the therapeutic landscape for pharmacists. <b>2021</b> , 37, 75-86	0
214	Changes in patient functioning and disability: results from a phase 3, double-blind, randomized, placebo-controlled clinical trial evaluating galcanezumab for chronic migraine prevention (REGAIN). <b>2021</b> , 30, 105-115	7
213	The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments. <b>2021</b> , 41, 247-255	2
212	Functional impairment and disability among patients with migraine: evaluation of galcanezumab in a long-term, open-label study. <b>2021</b> , 30, 455-464	3
211	Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial. <b>2021</b> , 41, 135-147	12

- 210 Quick Reference Guides of Commonly Prescribed Drugs and Doses. **2021**, 211-233
- 209 Prophylaxis of Migraine Protocols and Options. **2021**, 51-73
- 208 Monoclonal Antibodies as Neurological Therapeutics. **2021**, 14, 12
- 207 Chronic Migraine: An Update on Diagnosis and Management. **2021**, 69, S67-S75 1
- 206 Emerging Targets for Migraine Treatment. **2021**, 69, S98-S104 1
- 205 Neurological diseases: Sex and gender evidence in stroke, migraine, and Alzheimer's dementia. **2021**, 229-258
- 204 Psychometric validation and meaningful within-patient change of the Migraine-Specific Quality of Life questionnaire version 2.1 electronic patient-reported outcome in patients with episodic and chronic migraine. **2021**, 61, 511-526 2
- 203 Role of Monoclonal Antibodies against Calcitonin Gene-Related Peptide (CGRP) in Episodic Migraine Prevention: Where Do We Stand Today?. **2021**, 69, S59-S66
- 202 Galcanezumab. **2021**, 99-108 1
- 201 . **2021**, 4, 251581632110339
- 200 Migraine. **2021**,
- 199 A long-term open-label safety study of galcanezumab in Japanese patients with migraine. **2021**, 20, 721-733 4
- 198 Onset, Maintenance, and Cessation of Effect of Galcanezumab for Prevention of Migraine: A Narrative Review of Three Randomized Placebo-Controlled Trials. **2021**, 38, 1614-1626 3
- 197 Anti-CGRP monoclonal antibodies for migraine prevention: A systematic review and likelihood to help or harm analysis. **2021**, 41, 851-864 12
- 196 Effect of galcanezumab on severity and symptoms of migraine in phase 3 trials in patients with episodic or chronic migraine. **2021**, 22, 6 5
- 195 Migraine: Calcium Channels and Glia. **2021**, 22, 2
- 194 Relationship of the Calcitonin Gene-Related Peptide Monoclonal Antibody Galcanezumab Pharmacokinetics and Capsaicin-Induced Dermal Blood Flow in Healthy Subjects. **2021**, 10, 440-452
- 193 Efficacy and Tolerability of Calcitonin Gene-Related Peptide-Targeted Monoclonal Antibody Medications as Add-on Therapy to OnabotulinumtoxinA in Patients with Chronic Migraine. **2021**, 22, 1857-1863<sup>11</sup>

192	The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. <b>2021</b> , 268, 3789-3798	15
191	Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. <b>2021</b> , 22, 15	7
190	Galcanezumab for the prevention of migraine. <b>2021</b> , 11, 101-112	1
189	Pediatric Episodic Migraine with Aura: A Unique Entity?. <b>2021</b> , 8,	2
188	Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis. <b>2021</b> , 12, 649143	7
187	Targets for migraine treatment: beyond calcitonin gene-related peptide. <b>2021</b> , 34, 363-372	6
186	The Role of Galcanezumab in Migraine Prevention: Existing Data and Future Directions. <b>2021</b> , 14,	1
185	Severe migraine and its control: A proposal for definitions and consequences for care. <b>2021</b> , 177, 924-934	3
184	Partial and nonresponders to onabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: A real-world evidence study. <b>2021</b> , 28, 2378-2382	3
183	Real-World Evidence for Control of Chronic Migraine Patients Receiving CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA: A Retrospective Chart Review. <b>2021</b> , 10, 809-826	17
182	Pharmacokinetics and safety of ubrogepant when coadministered with calcitonin gene-related peptide-targeted monoclonal antibody migraine preventives in participants with migraine: A randomized phase 1b drug-drug interaction study. <b>2021</b> , 61, 642-652	14
181	Efficacy of galcanezumab in patients with migraine who did not benefit from commonly prescribed preventive treatments. <b>2021</b> , 21, 175	0
180	Treatment Satisfaction of Galcanezumab in Japanese Patients with Episodic Migraine: A Phase II Randomized Controlled Study. <b>2021</b> , 10, 265-278	2
179	Shift from high-frequency to low-frequency episodic migraine in patients treated with Galcanezumab: results from two global randomized clinical trials. <b>2021</b> , 22, 48	4
178	Diagnosis and Management of Headache: A Review. <b>2021</b> , 325, 1874-1885	20
177	Matching-adjusted indirect comparisons of oral rimegepant versus placebo, erenumab, and galcanezumab examining monthly migraine days and health-related quality of life in the treatment of migraine. <b>2021</b> , 61, 906-915	3
176	Grand rounds education in neurology, with a focus on headache medicine. <b>2021</b> , 61, 1077-1085	0
175	Calcitonin gene-related peptide in migraine: from pathophysiology to treatment. <b>2021</b> ,	0

174	E-diary use in clinical headache practice: A prospective observational study. <b>2021</b> , 41, 1161-1171	14
173	Galcanezumab Provides Consistent Efficacy Throughout the Dosing Interval Among Patients with Episodic and Chronic Migraine: A Post Hoc Analysis. <b>2021</b> , 38, 3154-3165	1
172	Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). <b>2021</b> , 22, 35	24
171	Effectiveness and Safety of CGRP-mAbs in Menstrual-Related Migraine: A Real-World Experience. <b>2021</b> , 10, 1203-1214	3
170	The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. <b>2021</b> , 61, 1021-1039	70
169	CGRP-antibodies, topiramate and botulinum toxin type A in episodic and chronic migraine: A systematic review and meta-analysis. <b>2021</b> , 41, 1222-1239	12
168	Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor. <b>2021</b> , 10, 469-497	1
167	Safety and tolerability of preventive treatment options for chronic migraine. <b>2021</b> , 20, 1523-1533	1
166	Benefit-Risk Assessment of Galcanezumab Versus Placebo for the Treatment of Episodic and Chronic Migraine Using the Metrics of Number Needed to Treat and Number Needed to Harm. <b>2021</b> , 38, 4442-4460	0
165	MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention. <b>2021</b> , 22, 74	4
164	Impact of Galcanezumab on Total Pain Burden: A Post Hoc Analysis of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Patients with Episodic Cluster Headache. <b>2021</b> , 14, 2059-2070	1
163	Indirect Comparison of Topiramate and Monoclonal Antibodies Against CGRP or Its Receptor for the Prophylaxis of Episodic Migraine: A Systematic Review with Meta-Analysis. <b>2021</b> , 35, 805-820	0
162	Calcitonin Gene-Related Peptide (CGRP) Antagonists: A comprehensive review of safety, efficacy and prescribing information. <b>2021</b> ,	1
161	Five-year experience of using a new class of drugs for targeted preventive therapy of migraine. <b>2021</b> , 26, 4-14	
160	Monoclonal Antibodies Targeting CGRP: From Clinical Studies to Real-World Evidence-What Do We Know So Far?. <b>2021</b> , 14,	4
159	Emerging drugs for the prevention of migraine. <b>2021</b> , 26, 271-280	0
158	Efficacy of calcitonin gene-related peptide (CGRP) receptor blockers in reducing the number of monthly migraine headache days (MHDs): A network meta-analysis of randomized controlled trials. <b>2021</b> , 427, 117505	3
157	Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. <b>2021</b> , 3331024211046617	8

156	The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events. <b>2021</b> , 17, 1223-1235	
155	Efficacy of galcanezumab in patients with migraine and history of failure to 3-4 preventive medication categories: subgroup analysis from CONQUER study. <b>2021</b> , 22, 113	2
154	Galcanezumab in Patients with Multiple Previous Migraine Preventive Medication Category Failures: Results from the Open-Label Period of the CONQUER Trial. <b>2021</b> , 38, 5465-5483	3
153	Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab. <b>2021</b> , 14,	0
152	The processes underlying chronic migraine pathophysiology and its treatment with botulinum toxin type A. <b>2021</b> , 9, 421	0
151	A critical review of the neurovascular nature of migraine and the main mechanisms of action of prophylactic antimigraine medications. <b>2021</b> , 21, 1035-1050	
150	Proportion of Women and Reporting of Outcomes by Sex in Clinical Trials for Alzheimer Disease: A Systematic Review and Meta-analysis. <b>2021</b> , 4, e2124124	6
149	An outlook on the trigeminovascular mechanisms of action and side effects concerns of some potential neuropeptidergic antimigraine therapies. <b>2021</b> , 17, 179-199	3
148	CGRP and Immune Modulation: Evidence-Based Therapy. <b>2021</b> , 75-94	1
147	Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes. <b>2021</b> , 22, 5	18
146	Immunogenicity of biologic therapies for migraine: a review of current evidence. <b>2021</b> , 22, 3	12
145	Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study. <b>2020</b> , 42, 2254-2265.e3	11
144	Calcitonin gene-related peptide (CGRP): role in migraine pathophysiology and therapeutic targeting. <b>2020</b> , 24, 91-100	25
143	Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. <b>2020</b> , 20, 627-641	27
142	Evolving options for the treatment of cluster headache. <b>2020</b> , 33, 323-328	3
141	Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. <b>2020</b> , 21, 55	18
140	Calcitonin Gene-Related Peptide Targeting Therapies for Migraine: A New Era for Migraine Treatment. <b>2020</b> , 38, 88-99	2
139	An Update On Migraine Treatment. <b>2020</b> , 38, 100-110	3

138	Migraine-Specific Quality-of-Life Questionnaire (MSQ) Version 2.1 Score Improvement in Japanese Patients with Episodic Migraine by Galcanezumab Treatment: Japan Phase 2 Study. <b>2020</b> , 13, 3531-3538	3
137	Novelty in Inflammation and Immunomodulation in Migraine. <b>2019</b> , 25, 2919-2936	16
136	Migraine - from pathophysiology to monoclonal antibodies. <b>2019</b> , 20, 296-300	0
135	CGRP monoclonal antibodies for migraine prophylaxis. <b>2019</b> , 20, 356-360	1
134	Managing Migraine in the Times of COVID-19 Pandemic. <b>2020</b> , 23, S33-S39	11
133	Therapeutic Management: When and What.	2
132	Galcanezumab for the Management of Migraine: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. <b>2020</b> , 12, e11621	3
131	CGRP and CGRP-receptor as targets of migraine therapy: Brain Prize-2021. <b>2021</b> ,	5
130	CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. <b>2021</b> , 22, 128	8
129	Update on Current Treatments for Migraine. <b>2018</b> , 14, 71	
128	Erenumab for the Prevention of Migraine, Including the Rationale, Findings and Clinical Implications of the LIBERTY Study. <b>2019</b> , 14, 68	
127	CGRP-Antagonisten zur Prävention von Migräne. <b>2019</b> , 30, 27-30	2
126	Neue und alte Substanzen in der Migräeprophylaxe. <b>2019</b> , 30, 14-15	
125	Galcanezumab in the prophylaxis of migraine. <b>2020</b> , 36, 59-66	
124	Migräne. <b>2020</b> , 1443-1460	
123	Migräne. <b>2020</b> , 1-18	
122	Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review. <b>2020</b> , 12, e8711	0
121	Galcanezumab for migraine. <b>2020</b> , 43, 135-136	

- 120 [Novel migraine treatment with CGRP-related monoclonal antibodies]. **2020**, 60, 668-676
- 119 CGRP Therapeutics For The Treatment Of Migraine [A Narrative Review]. 1
- 118 Neue Arzneimittel 2019. **2020**, 43-150 2
- 117 Emerging Treatment Options for Migraine. **2020**, 49, 226-235 1
- 116 Pharmacotherapy of migraine prevention based on the assessment of headache. **2020**, 63, 644-649 0
- 115 CGRP et migraine : ce qu'il faut savoir en 2020. **2020**, 33, 127-135
- 114 Headache and Facial Pain. **2021**, 265-287
- 113 Emerging Therapies for Patients With Difficult-to-Treat Migraine. **2018**, 43, 616-621 3
- 112 CGRP pathway treatments. **2022**, 215-221
- 111 Early Onset and Maintenance Effect of Galcanezumab in Japanese Patients with Episodic Migraine. **2021**, 14, 3555-3564 0
- 110 The Primary Care Management of Headache: Synopsis of the 2020 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline.. **2022**,
- 109 [CGRP antibodies in migraine prophylaxis : The new standard in migraine treatment?]. **2022**, 36, 59
- 108 Does "wearing off" of efficacy occur in galcanezumab-treated patients at the end of the monthly treatment cycle? Post hoc analyses of four phase III randomized trials.. **2022**, 2
- 107 Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment.. **2022**, 29, 1
- 106 Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide's Motor-Stimulating and Prosecretory Function in the Intestine.. **2021**, 12, 820006 3
- 105 Alpha-Calcitonin Gene Related Peptide: New Therapeutic Strategies for the Treatment and Prevention of Cardiovascular Disease and Migraine.. **2022**, 13, 826122 1
- 104 Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.. **2022**, 0
- 103 Efficacy and safety of calcitonin gene-related peptide antagonists in migraine treatment: A meta-analysis.. **2022**, e2542 2

102	Safety and tolerability of fremanezumab in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies.. <b>2022</b> , 3331024221076485	2
101	New Insights on Metabolic and Genetic Basis of Migraine: Novel Impact on Management and Therapeutical Approach.. <b>2022</b> , 23,	0
100	Real-world efficacy of galcanezumab for the treatment of migraine in Korean patients.. <b>2022</b> , 3331024221076481	1
99	Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.. <b>2022</b> , 23, 40	1
98	The under-recognized but essential role of the limbic system in the migraine brain: a narrative review. <b>2022</b> , 6, 2-8	
97	Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine.. <b>2022</b> ,	2
96	Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study.. <b>2022</b> , 1-34	2
95	In search of a gold standard patient-reported outcome measure to use in the evaluation and treatment-decision making in migraine prevention. A real-world evidence study.. <b>2021</b> , 22, 151	4
94	Deterioration of headache impact and health-related quality of life in migraine patients after cessation of preventive treatment with CGRP(-receptor) antibodies.. <b>2021</b> , 22, 158	1
93	Impact of age and sex on the efficacy of fremanezumab in patients with difficult-to-treat migraine: results of the randomized, placebo-controlled, phase 3b FOCUS study.. <b>2021</b> , 22, 152	1
92	Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.. <b>2021</b> , 22, 154	5
91	Next generation antibody-based therapies in neurology.. <b>2021</b> ,	2
90	The Arrival of Anti-CGRP Monoclonal Antibodies in Migraine.. <b>2022</b> , 1	1
89	Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale.. <b>2022</b> ,	2
88	Vestibular Migraine: Clinical Aspects and Pathophysiology.. <b>2022</b> ,	0
87	The significance of correct algorithm of the diagnostics and treatment of migraine in the prophylactic treatment against calcitonin gene-related peptide. <b>2022</b> , 23, 138-145	
86	Treatment of migraine with monoclonal antibodies.. <b>2022</b> ,	
85	Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials.. <b>2022</b> , 1-35	2



84	Calcitonin gene-related peptide (CGRP) is a key molecule released in acute migraine attacks-Successful translation of basic science to clinical practice.. <b>2022</b> ,	2
83	Brazilian descriptive study of 104 consecutive real-world migraine patients treated with monoclonal antibodies.. <b>2022</b> ,	
82	The importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. <b>2022</b> , 15, 175628642210959	1
81	Cardiovascular Disease and Migraine: Are the New Treatments Safe?.	1
80	The ultimate guide to the anti-CGRP monoclonal antibodies galaxy.	0
79	Galcanezumab effect on whole pain burden and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience. <b>2022</b> , 23,	4
78	European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention 2022 update. <b>2022</b> , 23,	13
77	Galcanezumab modulates Capsaicin-induced C-fiber reactivity. 033310242211129	0
76	Efficacy and Safety of Galcanezumab for Migraine: Evidences From Direct and Indirect Comparisons. 1-15	
75	Recently approved and emerging drug options for migraine prophylaxis.	0
74	CGRP-Targeted Therapy for Episodic and Chronic Cluster Headache.	1
73	Migraine management: an update for the 2020s. <b>2022</b> , 52, 1123-1128	1
72	It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine. <b>2022</b> , 80, 218-226	
71	Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study. <b>2022</b> , 23,	0
70	Reducing the Burden of Migraine: Safety and Efficacy of CGRP Pathway-Targeted Preventive Treatments. <b>2022</b> , 11, 4359	1
69	ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential. <b>2022</b> , 11, 2406	2
68	Reductions in acute medication use and healthcare resource utilization in patients with chronic migraine: a secondary analysis of a phase 3, randomized, double-blind, placebo-controlled study of galcanezumab with open-label extension (REGAIN). <b>2022</b> , 25, 1030-1038	1
67	Headache: Treatment update. <b>2022</b> , 100420	1

66	Outpatient Approach to Resistant and Refractory Migraine in Children and Adolescents: a Narrative Review.	1
65	Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post-Hoc Analysis.	1
64	Treatment. <b>2022</b> , 639-881	0
63	Atogepant for the prevention of episodic migraine in adults. <b>2022</b> , 10, 205031212211286	0
62	Placebo response with subcutaneous injections in calcitonin gene-related peptide receptor monoclonal antibody migraine preventative trials: A systematic review and meta-analysis. <b>2022</b> , 5, 251581632211201	0
61	Preventive Treatment of Migraine.	0
60	Impact of fremanezumab on disability outcomes in patients with episodic and chronic migraine: a pooled analysis of phase 3 studies. <b>2022</b> , 23,	1
59	Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis. <b>2022</b> , 15, 1189	0
58	Maintenance of response and predictive factors of 1-year Galcanezumab treatment in real-life migraine patients in Italy : The multicenter prospective cohort GARLIT study.	3
57	Efficacy and safety of monoclonal antibody against calcitonin gene-related peptide or its receptor for migraine patients with prior preventive treatment failure: a network meta-analysis. <b>2022</b> , 23,	0
56	A phase IV clinical trial of gastrointestinal motility in adult patients with migraine before and after initiation of a calcitonin gene-related peptide ligand (galcanezumab) or receptor (erenumab) antagonist.	0
55	New Approaches to Shifting the Migraine Treatment Paradigm. 3,	0
54	Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review.	2
53	Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment.	0
52	The importance of an early onset of migraine preventive disease control: A roundtable discussion. <b>2022</b> , 5, 251581632211345	0
51	Consensus of the Brazilian Headache Society (SBCe) for the Prophylactic Treatment of Episodic Migraine: part I. <b>2022</b> , 80, 845-861	0
50	Migraine treatment in patients with poor compliance. <b>2022</b> , 23, 324-329	0
49	Chronic Migraine. <b>2022</b> ,	0

48	Involvement of the cerebellum in migraine. 16,	o
47	Galcanezumab Effects on Migraine Severity and Symptoms in Japanese Patients with Episodic Migraine: Secondary Analysis of a Phase 2 Randomized Trial.	o
46	Description of the response to galcanezumab in 7 patients with refractory cluster headache. A review and a case series.. <b>2022</b> ,	o
45	Migraine Therapy: New Horizons and Beyond. <b>2021</b> , 110, 2449-2457	o
44	Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials.	o
43	Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System.	o
42	Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies: Adverse Effects. What Do We Really Know? A Literature Review. 64-72	1
41	Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States. 1-15	o
40	Calcitonin Gene-Related Peptide (CGRP)-Targeted Treatments New Therapeutic Technologies for Migraine. <b>2023</b> , 3, 117-131	o
39	The Temporal Trend of Placebo Response in Migraine Prevention from 1990 to 2021: A Systematic Literature Review and Meta-Analysis with Regression.	o
38	Photophobia and migraine outcome during treatment with galcanezumab. 13,	o
37	Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data. <b>2023</b> , 12, 143	o
36	Advances in Antibody-Based Therapeutics for Cerebral Ischemia. <b>2023</b> , 15, 145	o
35	Trigeminal Autonomic Cephalalgias. <b>2023</b> , 131-319	o
34	Comorbidity or combination [more evidence for cluster-migraine?. <b>2023</b> , 43, 033310242211333	o
33	Intensive Mindfulness Meditation Reduces Frequency and Burden of Migraine: An Unblinded Single-Arm Trial.	o
32	Monoclonal CGRP- (R) antibodies for the prevention of migraine. <b>2023</b> , 22, 4-6	o
31	One-Time Use of Galcanezumab or Fremanezumab for Migraine Prevention. <b>2023</b> ,	o

- 30 Targeting the Brain with Single-Domain Antibodies: Greater Potential Than Stated So Far?. **2023**, 24, 2632 ○
- 29 Medication-overuse Headache: Diagnostic Criteria, Epidemiology, and Treatment. **2023**, 41, 1-10 ○
- 28 Alopecia as an emerging adverse event to CGRP monoclonal antibodies: Cases Series, evaluation of FAERS, and literature review. **2023**, 43, 033310242211435 ○
- 27 Calcitonin gene-related peptide (CGRP) monoclonal antibodies for migraine. pn-2022-003592 ○
- 26 New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. **2023**, 43, 033310242211463 1
- 25 Migraine Disability Improvement during Treatment with Galcanezumab in Patients with Chronic and High Frequency Episodic Migraine. **2023**, 15, 273-284 ○
- 24 Pre-treatment non-ictal cephalic allodynia identifies responders to prophylactic treatment of chronic and episodic migraine patients with galcanezumab: A prospective quantitative sensory testing study (NCT04271202). **2023**, 43, 033310242211478 ○
- 23 Safety and tolerability of monoclonal antibodies targeting the CGRP pathway and gepants in migraine prevention: A systematic review and network meta-analysis. **2023**, 43, 033310242311521 ○
- 22 Changes in migraine interictal burden following treatment with galcanezumab: Results from a phase III randomized, placebo-controlled study. ○
- 21 Predictors of response to galcanezumab in patients with chronic migraine: a real-world prospective observational study. ○
- 20 Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience. **2023**, 24, ○
- 19 Predictors of galcanezumab response in a real-world study of Korean patients with migraine. ○
- 18 An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor. ○
- 17 Evaluating the efficacy of CGRP mAbs and gepants for the preventive treatment of migraine: A systematic review and network meta-analysis of phase 3 randomised controlled trials. **2023**, 43, 033310242311593 ○
- 16 Headaches. **2023**, 121-138 ○
- 15 Galcanezumab. **2019**, 41, ○
- 14 Wearing-off Efficacy of CGRP monoclonal antibodies for migraine prevention: A meta-analysis of randomized controlled trials. **2023**, 43, 033310242311612 ○
- 13 Calcitonin gene relating peptide inhibitors in combination for migraine treatment: A mini-review. 4, ○

- 12 Anwendung monoklonaler Antikörper zur Migräprophylaxe in der Praxis. **2023**, 25, 30-39 ○
- 11 Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study. 14, ○
- 10 Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study. **2023**, 24, ○
- 9 Galcanezumab effects on incidence of headache after occurrence of triggers, premonitory symptoms, and aura in responders, non-responders, super-responders, and super non-responders. **2023**, 24, ○
- 8 Advances in CGRP monoclonal antibodies as migraine therapy: A narrative review. **2023**, 11, 11 ○
- 7 Glia Signaling and Brain Microenvironment in Migraine. ○
- 6 A Review of Tangential Flow Filtration: Process Development and Applications in the Pharmaceutical Industry. **2023**, 27, 571-591 ○
- 5 Hellenic Headache Society Recommendations for the Use of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide Pathway for the Prevention of Migraine and Cluster Headache 2023 Update. **2023**, 5, ○
- 4 Migraine: from pathophysiology to treatment. ○
- 3 What's new in migraine therapy?. **2023**, 36, 123-128 ○
- 2 Emerging drugs for the preventive treatment of migraine: a review of CGRP monoclonal antibodies and gepants trials. 1-18 ○
- 1 The temporal trend of placebo response in migraine prevention from 1990 to 2021: a systematic literature review and meta-analysis with regression. **2023**, 24, ○